ArticleJTO clinical and research reports2022

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial.

Hui Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.